Predictions
Lexicon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.66
13.12.20
13.12.20
-
13.12.21
13.12.21
143.95%
16.02.21
16.02.21
Probably not worthwhile Investment
Significant cyclical dependencies
Cisco Systems Inc.
Start price
Target price
Perf. (%)
€36.70
12.12.20
12.12.20
-
12.12.21
12.12.21
6.27%
15.02.21
15.02.21
Fair valuation
High dividend yield expected
Higher risks for its business
Cisco Systems Inc.
Start price
Target price
Perf. (%)
€36.70
12.12.20
12.12.20
-
12.12.21
12.12.21
6.27%
15.02.21
15.02.21
Fair valuation
High dividend yield expected
Higher risks for its business
Cisco Systems Inc.
Start price
Target price
Perf. (%)
€36.70
12.12.20
12.12.20
-
12.12.21
12.12.21
6.27%
15.02.21
15.02.21
Fair valuation
High dividend yield expected
Higher risks for its business
Cisco Systems Inc.
Start price
Target price
Perf. (%)
€36.70
12.12.20
12.12.20
-
12.12.21
12.12.21
6.27%
15.02.21
15.02.21
Fair valuation
High dividend yield expected
Higher risks for its business
Verrica Pharmaceuticals
Start price
Target price
Perf. (%)
€8.75
12.12.20
12.12.20
-
12.12.21
12.12.21
-2.29%
13.12.21
13.12.21
Probably not worthwhile Investment
Inseego Corp.
Start price
Target price
Perf. (%)
€12.26
12.12.20
12.12.20
-
12.12.21
12.12.21
-54.63%
13.12.21
13.12.21
Probably not worthwhile Investment
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€395.05
12.12.20
12.12.20
-
12.12.21
12.12.21
4.78%
09.01.21
09.01.21
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€395.05
12.12.20
12.12.20
-
12.12.21
12.12.21
4.78%
09.01.21
09.01.21
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€395.05
12.12.20
12.12.20
-
12.12.21
12.12.21
4.78%
09.01.21
09.01.21
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Mercadolibre Inc
Start price
Target price
Perf. (%)
€1,335.8
12.12.20
12.12.20
-
12.12.21
12.12.21
6.06%
09.01.21
09.01.21
Could be worthwhile Investment >10% per year
Some uniques
Medium risks for its business
Top 10 in its market
Mercadolibre Inc
Start price
Target price
Perf. (%)
€1,335.8
12.12.20
12.12.20
-
12.12.21
12.12.21
6.06%
09.01.21
09.01.21
Could be worthwhile Investment >10% per year
Some uniques
Medium risks for its business
Top 10 in its market
Borgwarner Inc.
Start price
Target price
Perf. (%)
€30.40
12.12.20
12.12.20
-
12.12.21
12.12.21
21.71%
14.09.21
14.09.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Pfizer Inc.
Start price
Target price
Perf. (%)
€35.01
12.12.20
12.12.20
-
12.12.21
12.12.21
-14.23%
24.03.21
24.03.21
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Pfizer Inc.
Start price
Target price
Perf. (%)
€35.01
12.12.20
12.12.20
-
12.12.21
12.12.21
-14.23%
24.03.21
24.03.21
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Deutsche Lufthansa AG
Start price
Target price
Perf. (%)
€9.35
12.12.20
12.12.20
-
12.12.21
12.12.21
18.32%
24.03.21
24.03.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Home Depot Inc.
Start price
Target price
Perf. (%)
€218.45
12.12.20
12.12.20
-
12.12.21
12.12.21
12.86%
24.03.21
24.03.21
Fair valuation
High dividend yield expected
Valuable balance sheet
Little Investments for future growth
Home Depot Inc.
Start price
Target price
Perf. (%)
€218.45
12.12.20
12.12.20
-
12.12.21
12.12.21
12.86%
24.03.21
24.03.21
Fair valuation
High dividend yield expected
Valuable balance sheet
Little Investments for future growth
Overstock.com
Start price
Target price
Perf. (%)
€45.56
12.12.20
12.12.20
-
12.12.21
12.12.21
74.51%
08.02.21
08.02.21
Stable Large shareholder and/or long term investor
EBIT decline/stagnation expected
Few uniques
Sustainability is little important
vTv Therapeutics Inc
Start price
Target price
Perf. (%)
€2.30
12.12.20
12.12.20
€1.00
12.12.21
12.12.21
-14.22%
26.06.21
26.06.21
Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
overvalued
Sonoma Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€6.90
12.12.20
12.12.20
€3.00
12.12.21
12.12.21
-8.48%
26.06.21
26.06.21
Risky Investment
Revenue decline > 20% expected
Decining EBIT margin than peer group
EBIT decline > 20% expected